Universität zu Köln

Abken, Hinrich (2015). Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors. Immunotherapy, 7 (5). S. 535 - 545. LONDON: FUTURE MEDICINE LTD. ISSN 1750-7448

Full text not available from this repository.

Abstract

Recent spectacular success in the adoptive cell therapy of leukemia and lymphoma with chimeric antigen receptor (CAR)-modified T cells raised the expectations that this therapy may be efficacious in a wide range of cancer entities. The expectations are based on the predefined specificity of CAR T cells by an antibody-derived binding domain that acts independently of the natural T-cell receptor, recognizes targets independently of presentation by the major histocompatibility complex and allows targeting toward virtually any cell surface antigen. We here discuss that targeting CAR T cells toward solid tumors faces certain circumstances critical for the therapeutic success. Targeting tumor stroma and taking advantage of TRUCK cells, in other words, CAR T cells with inducible release of a transgenic payload, are some strategies envisaged to overcome current limitations in the near future.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Abken, Hinrich UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-419020
DOI:	10.2217/IMT.15.15
Journal or Publication Title:	Immunotherapy
Volume:	7
Number:	5
Page Range:	S. 535 - 545
Date:	2015
Publisher:	FUTURE MEDICINE LTD
Place of Publication:	LONDON
ISSN:	1750-7448
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CHIMERIC ANTIGEN RECEPTORS; PHASE-I; GENETIC-MODIFICATION; ESTABLISHED TUMORS; ANTITUMOR-ACTIVITY; ADVERSE EVENT; IMMUNOTHERAPY; PERSISTENCE; LYMPHOCYTES; EXPRESSION Multiple languages Immunology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/41902